Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H17N3O4S |
Molecular Weight | 311.357 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2
InChI
InChIKey=LVWZTYCIRDMTEY-UHFFFAOYSA-N
InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)
DescriptionSources: http://www.un.org/esa/coordination/CL12.pdf
Sources: http://www.un.org/esa/coordination/CL12.pdf
Dipyrone, also known as Metamizole (INN), is an ampyrone sulfonate analgesic, antispasmodic and antipyretic. It was withdrawn from US market in 1977 on the basis of reports of agranulocytosis. Depyrone is still used to treat severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. Mechanism of action of dipyrone is complex. It is believed that dipyrone exerts its action by inhibiting COX-3, and activates opioid and cannabioid systems either itself, or by products of its metabolic degradation.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NEURALGIN Approved UseSevere and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. |
|||
Primary | OPTALGIN Approved UseOptalgin Injection, by intramuscular administration, is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision. |
PubMed
Title | Date | PubMed |
---|---|---|
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. | 1984 |
|
Mode of analgesic action of dipyrone: direct antagonism of inflammatory hyperalgesia. | 1985 Aug 27 |
|
Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships. | 1987 Nov |
|
Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. | 1996 Jun |
|
Use of dipyrone during pregnancy and risk of Wilms' tumor. Brazilian Wilms' Tumor Study Group. | 1996 Sep |
|
Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action. | 1998 Mar 26 |
|
Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations. | 2001 Dec |
|
Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. | 2002 Dec |
|
A comparative study of the antipyretic effects of indomethacin and dipyrone in rats. | 2002 Jan |
|
[Postoperative analgesia with tramadol and metamizol. Continual infusion versus patient controlled analgesia]. | 2003 Jan |
|
[Multifocal brain haemorrhage associated with migraine and medication abuse]. | 2003 Nov 1-15 |
|
Antinociceptive profile of (-)-spectaline: a piperidine alkaloid from Cassia leptophylla. | 2003 Sep |
|
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam. | 2004 Jun |
|
[Acute intermittent porphyria and oral contraception. Case report]. | 2006 Mar |
|
Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS). | 2009 Jun |
Sample Use Guides
Dipyrone was administered orally, as subcutaneous and intramuscular injections (daily dose 0.25-1 g as 50% solution), or by intravenous injection.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329
Cyclooxygenase activity was measured by the formation of PGE2 after exposure to exogenous 30 μM acid for 10 min. Dipyrone inhibited COX-1 with IC50 350 uM, and COX-3 with IC50 of 52 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BB72
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
||
|
WHO-ATC |
N02BB52
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB03187MIG
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
934T64RMNJ
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
DTXSID6044143
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
4659
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
DB04817
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
934T64RMNJ
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
3111
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
50567-35-6
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
METAMIZOLE
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
256-627-7
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY | |||
|
100000085923
Created by
admin on Fri Dec 15 16:27:12 UTC 2023 , Edited by admin on Fri Dec 15 16:27:12 UTC 2023
|
PRIMARY |
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PRODRUG)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD